64.98 -0.50 (-0.76%)
After hours: 4:48PM EST
|Bid||60.81 x 1200|
|Ask||68.45 x 800|
|Day's Range||63.97 - 65.70|
|52 Week Range||61.05 - 78.38|
|Beta (3Y Monthly)||1.21|
|PE Ratio (TTM)||30.00|
|Earnings Date||Jan 31, 2019|
|Forward Dividend & Yield||0.76 (1.17%)|
|1y Target Est||74.00|
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]
Daniel Loeb (Trades, Portfolio), whose fund is posting negative returns this year, reported on Wednesday that he unloaded a portion of one of his highly profitable bets, health care company Baxter International (BAX). Warning! GuruFocus has detected 1 Warning Sign with GOOG. The sale resulted from the "portfolio concentration level" it had reached in the portfolio of his hedge fund, Third Point.
Baxter International Inc. (BAX), a global leader in clinical nutrition, is collaborating with the European Foundation for the Care of Newborn Infants (EFCNI) to raise awareness for the new EFCNI standards that address the disparities in newborn care in Europe. EFCNI released the new European Standards of Care for Newborn Health last week.
Baxter International Inc. (BAX), a leading global medical products company, today announced it has appointed Patricia B. (Patty) Morrison, former Cardinal Health executive vice president and chief information officer, and Amy A. Wendell, former Covidien senior vice president of strategy and business development, to its board of directors.
Baxter International Inc. , a leading global medical products company, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. José E. Almeida, Baxter’s chairman and chief executive officer, is scheduled to present on Monday, January 7, 2019 at 10 a.m.
Today I will examine Baxter International Inc’s (NYSE:BAX) latest earnings update (30 September 2018) and compare these figures against its performance over the past couple of years, in addition to Read More...
In November, among the 22 analysts covering Edwards Lifesciences (EW), 13 recommended a “buy” or higher rating, seven recommended a “hold” rating, and two recommended a “sell” or lower rating. The mean rating for Edwards Lifesciences stock is 2.32 with a target price of $161.53, which implies an upside potential of 4.5% over Edwards Lifesciences’ closing price of $154.52 on November 27.
General Electric’s (GE) Healthcare segment, which offers medical imaging and information technologies, biopharmaceutical manufacturing technologies, and patient monitoring systems, is one of the company’s better-performing units and is the fourth-largest contributor to its total revenue.
In November, among the 17 analysts covering Baxter International (BAX), ten analysts recommended a “buy” or a higher rating, five recommended a “hold” rating, and three recommended a “sell” rating. The mean rating for Baxter International stock is 2.29 with a target price of $73.27, which implies an upside potential of 11.3% over Baxter International’s closing price of $65.83 on November 15.
Baxter International’s (BAX) cost of sales decreased from $1.58 billion in the third quarter of 2017 to $1.53 billion in the third quarter. The company’s gross profit increased from $1.13 billion in the third quarter of 2017 to $1.24 billion in the third quarter due to the favorable product mix and manufacturing efficiencies.
Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018. In this series, we’ll discuss Baxter International’s financials, analysts’ views on the stock, valuation metrics, and geographic performance. The company’s business units include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery, and acute therapies.
Baxter International’s (BAX) net interest expense decreased from $14.0 million in the third quarter of 2017 to $11.0 million in the third quarter. The company’s net other income increased from $4.0 million in the third quarter of 2017 to $32.0 million in the third quarter. While the company incurred an income tax expense of $42.0 million in the third quarter of 2017, it received an income tax benefit of $138.0 million in the third quarter.
Baxter International Inc. (BAX), a global leader in advancing surgical innovation, revealed its Peri-Strips Dry with Veritas (PSDV) Circular Staple Line Reinforcement with Secure Grip technology, the latest evolution in a product portfolio that has more than 20 years of proven clinical use in surgical buttressing and soft tissue repair. PSDV Circular is being showcased alongside the company’s comprehensive Advanced Surgery portfolio at the 2018 American Society for Metabolic and Bariatric Society (ASMBS) – Obesity Week meeting this week.
As part of its major restructuring plan, General Electric (GE) intends to spin off its Healthcare segment and turn it into a standalone entity. The company has planned the spin-off in a manner that maximizes shareholder wealth.
Baxter International Inc. said Tuesday its board has approved a $2 billion increase to its share buyback authorization, bringing the total available to $3.4 billion. The medical products company's shares were up 1.1% premarket, but have fallen about 5% in 2018, while the S&P 500 has gained 2%.
Baxter International Inc. (BAX), a leading global medical products company, announced today a quarterly cash dividend and an expanded authorization for its share repurchase program. Baxter’s Board of Directors has also approved a $2.0 billion increase in authorization for the company’s existing share repurchase plan. Based on these actions, the share repurchase plan has approximately $3.4 billion of repurchase authority available as of the date hereof to make repurchases pursuant to new or existing Rule 10b5-1 plans or otherwise.
Studies examine cancer-related malnutrition and nutrition management in pre-term babies, as well as the use of hemostats in specific pancreatic and spinal surgeries
Baxter International Inc. (BAX), a global leader in advancing surgical innovation, today unveiled the latest design enhancements for its fibrin sealant product, the Tisseel Prima syringe, at the 2018 American Association of Gynecologic Laparoscopists (AAGL) meeting. Attendees can visit Baxter’s booth #807 at the AAGL meeting this week for product demonstrations of the new Prima syringe and the Tisseel 40cm Duplotip Rigid Applicator, along with the rest of Baxter’s portfolio of hemostats and sealants that can be used during gynecological surgeries.
Baxter International Inc. , a leading global medical products company, will present at Citi’s 2018 Global Healthcare Conference on Thursday, December 6, 2018, in New York.